# Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies

> **NCT01548521** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 5 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** Oxytocin

## Key facts

- **NCT ID:** NCT01548521
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-02
- **Final completion:** 2012-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548521, "Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01548521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*